|Genomic Announces Presentation Of Five Studies In Breast And Colon Cancers. Inovio's PENNVAX-G Global HIV Vaccine Achieves 100% Antigen-Specific T-Cell Immune Responses.|
|By Staff and Wire Reports|
|Tuesday, 13 September 2011 19:48|
Genomic Health, Inc. (NASDAQ:GHDX) announced results of five studies covering breast and colon cancers which will be presented during poster sessions at the 2011 European Multidisciplinary Cancer Congress, September 23-27, in Stockholm, Sweden.
Breast cancer presentations include health economics analysis of seven studies in six countries supporting Oncotype DX's cost effectiveness across various healthcare systems. Breast cancer data also includes a study from Japan reconfirming that use of Oncotype DX reduces use of chemotherapy in early-stage breast cancer patients, including those with lymph node positive status.
Additionally, studies from Israel and Greece reinforce prior findings that the Oncotype DX Recurrence Score (RS) cannot be predicted by traditional clinicopathologic measures. The Company also will present results across multiple clinical endpoints from a second large study of the Oncotype DX Colon Cancer test confirming its ability to predict recurrence risk for stage II colon cancer, providing information not available with conventional prognostic factors.
Inovio Pharmaceuticals, Inc. (AMEX:INO) announced that early data from a Phase I study assessing its PENNVAX-G global HIV vaccine plus a virus vector vaccine, Modified Vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR), as a unique prime-boost preventive HIV vaccination strategy has demonstrated strong immune responses and safety. These results were presented at the AIDS Vaccine Conference in Bangkok, Thailand.
This interim data was from the first cohort of 11 healthy subjects enrolled in the US as part of the first phase of the study to assess safety of the prime-boost combination vaccine. Enrollment will now continue in three sites in Africa in the next phase of the study. The study is being conducted by the U.S. Military HIV Research Program (MHRP) through its clinical research network in the US and Africa.
This clinical trial was designed to test safety and immunogenicity of a unique heterologous DNA/recombinant poxvirus prime-boost preventive HIV immunization strategy aimed at global coverage. Early analysis of this initial data revealed a strong cell-mediated immune response, with CD4+ and CD8+ T cells specific for both the gag and env antigens encoded by the prime and boost agents.
Attracting one of med-tech's most inspiring leaders, Boston Scientific Corporation (NYSE: BSX) has named Michael Mahoney, 46, as President of the Company, effective October 17, 2011.
Bristol-Myers Squibb Company (NYSE: BMY) will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, September 15, 2011, in London.
Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that its HearTwave II System was cleared for sale by the Mexican regulatory authorities.
Champions Oncology, Inc. formerly Champions Biotechnology, Inc. (OTC: CSBR) reported the following results: Fiscal Year 2012 First Quarter Financial Results: Total operating revenues for the first quarter of fiscal 2012 were $1.63 million compared to $1.60 million in the first quarter of fiscal 2011.
Genmed Holding Corp. (OTCBB: GENM) has announced that in preparation for its initial shipments to its distributors the Company has made an addition to its management team.
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible catheter robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced today that President and CEO Bruce Barclay is scheduled to present at the UBS Global Life Sciences Conference.
Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the Bank of America Merrill Lynch Healthcare Conference will be webcast and may be accessed at www.hgsi.com.
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of September 12, 2011 to March 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended September 7, 2011, in addition to the continued accrual of the original issue discount.
Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement on GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's vaccine to protect against certain diseases caused by human papillomavirus (HPV) types 6, 11, 16 and 18.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the UBS Global Life Sciences Conference in New York.
Pall Corporation (NYSE:PLL) today introduced the new compact, easy-to-use Sentino Microbiology Pump for microbial analysis of aqueous samples using the Membrane Filter (MF) Technique.
Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes.
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 9:30 a.m. Eastern Time.
UBS (NYSE: UBS): WHAT: UBS’s Annual Global Life Sciences Conference, one of the industry’s largest, will feature presentations from executives of approximately 270 companies in the following life sciences sectors: Biotechnology, Life Sciences Tools, Medical Technology, Pharmaceuticals and Specialty Pharmaceuticals.
ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze™ technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE).